野村發表研報指，藥明康德(02359.HK)今年首季業績表現符合預期，收入按年跌11%，盈利按年跌10%。由於銷售開支比率提升0.3個百分點至2.2%，拖累期內經營溢利率下降2.1個百分點至24%，毛利率亦收窄至37.3%。
管理層仍維持2024年業績指引不變，野村目前對藥明康德的投資評級為「買入」，目標價54.56元。
《大行》野村：藥明康德(02359.HK)首季業績符預期 維持今年指引
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.